
Rybrevant & Lazertinib: Combating Lung Cancer Resistance
New data from the MARIPOSA study shows that the Rybrevant (amivantamab-vmjw) and Lazertinib combination significantly reduces resistance development in patients with EGFR-mutated non-small cell lung cancer (NSCLC) compared to osimertinib, extending survival. This builds on previously reported overall survival benefits.


